UpStream Bio Inc. UPB 深 沪
等待开盘 12-17 09:30:00 美东时间
29.32
+2.120
+7.79%
华盛通- 最 高29.725
- 今 开26.92
- 成交量 93.20万股
- 最 低 26.03
- 昨 收 27.20
- 总市值 15.84亿
- 52周最高 33.00
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 5.14
- 委 比 -28.18%
- 总股本 5403.86万
- 历史最高 33.00
- 量 比 1.61
- 振 幅 13.58%
- 历史最低 5.14
- 每 手 1
- 风险率 6.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 最高500美元！MongoDB获18家大行紧急上调目标价；巴克莱下调理想汽车目标价至18美元
今日重点评级关注：B. Riley证券：维持Seabridge Gold"买入"评级，目标价从50美元升至65美元；HC Wainwright & Co.：维持TRX Gold"买入"评级，目标价从1.2美元升至1.4美元
12-03 09:58
LifeSci Capital Initiates Coverage On Upstream Bio with Outperform Rating, Announces Price Target of $43
LifeSci Capital initiates coverage on Upstream Bio (NASDAQ:UPB) with a Outperform rating and announces Price Target of $43.
12-02 20:54
美股大行评级 | Stifel上调英伟达目标价升至250美元；大摩上调哔哩哔哩目标价升至27美元；NICE遭多家机构下调目标价
今日重点评级关注：Oppenheimer：维持Olema Pharmaceuticals"跑赢大市"评级，目标价从22美元升至45美元；Bernstein：维持Atlassian"跑赢大市"评级，目标价从290美元升至304美元
11-19 11:01
Evercore ISI Group Initiates Coverage On Upstream Bio with Outperform Rating, Announces Price Target of $40
Evercore ISI Group analyst Cory Kasimov initiates coverage on Upstream Bio (NASDAQ:UPB) with a Outperform rating and announces Price Target of $40.
11-18 20:39
Upstream Bio Q3 EPS $(0.63) Beats $(0.76) Estimate, Sales $683.000K Beat $645.000K Estimate
Upstream Bio (NASDAQ:UPB) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.76) by 17.54 percent. This is a 90.95 percent increase over losses of $(6.96) per share from the
11-05 20:16
美股大行评级 | 麦格理首予哔哩哔哩"跑赢大市"评级，目标价36.03美元； 高盛首予联合健康集团"买入"评级，目标价406美元
今日重点评级关注：摩根士丹利：上调Alvotech评级至"超配"，目标价14美元；蒙特利尔银行：维持PG&E"跑赢大市"评级，目标价从23美元升至25美元
10-15 18:20
Truist Securities Initiates Coverage On Upstream Bio with Buy Rating, Announces Price Target of $47
Truist Securities analyst Danielle Brill initiates coverage on Upstream Bio (NASDAQ:UPB) with a Buy rating and announces Price Target of $47.
10-14 21:09
Upstream Bio Highlights New Respiratory Drug Verekitug With Trial Data
Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented structural and mechanistic data showing
09-30 16:26
Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress
Upstream Bio presented data on verekitug, a novel antibody targeting the TSLP receptor, showing its potent inhibition of TSLP receptor activity, rapid and sustained effects in patients with chronic rhinosinusitis, and potential for less frequent dosing compared to existing therapies. Verekitug demonstrated high affinity binding to the TSLP receptor, outcompeting TSLP and blocking its signaling, with Phase 2 data showing significant clinical benef...
09-30 08:15
Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum
Upstream Bio, Inc. (Nasdaq: UPB), a company developing treatments for inflammatory diseases with a focus on severe respiratory disorders, announced that CEO Rand Sutherland will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation Forum on September 15, 2025, at 10:30 a.m. ET. The event will be webcast live and available for replay on the Company's website. Upstream Bio is advancing verekitug, a monoclonal antibod...
09-09 11:00
